Huajian Medical, alongside its subsidiaries, signs a strategic $1.5 billion cooperation agreement with Transcenta Group to focus on tokenizing drug pipeline assets as Real-World Assets (RWAs).
Huajian Medical, in collaboration with its subsidiaries ETHK Inc and ETHK Holdings Limited, has signed a strategic cooperation agreement valued at $1.5 billion with Transcenta Group and Transcenta Oncology Inc. The partnership will explore tokenizing innovative drug pipeline assets as Real-World Assets (RWAs), advancing blockchain-based financial infrastructure in the healthcare sector.